Skip to main content
  • Home
  • Articles
    • Archive from 2022 July
    • Archive 1960 to 2022 June
    • Accepted Articles
    • Published Ahead-of-Print
    • Supplement
  • About
  • For Authors
  • Podcasts

Ertapenem susceptibility of extended spectrum a-lactamase-producing Enterobacteriaceae at a tertiary care centre in India

< Back to Listing

Share this Article

Singapore Med J 2009; 50(6): 628-632
Ertapenem susceptibility of extended spectrum a-lactamase-producing Enterobacteriaceae at a tertiary care centre in India

  • Abstract
  • PDF

Behera B, Mathur P, Das A, Kapil A
Correspondence: Dr Purva Mathur, purvamathur@yahoo.co.in

ABSTRACT
Introduction
Infections caused by multidrug-resistant organisms such as extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have come to assume widespread proportions. Carbapenems (imipenem and meropenem) are the drugs of choice for the treatment of infections caused by ESBL-producing organisms. There is limited clinical data regarding the efficacy of the latest carbapenem, called ertapenem, against these organisms in the Indian subcontinent. In this study, ertapenem susceptibility in ESBL-producing clinical isolates was evaluated. The in vitro activities of the three carbapenems were compared in ertapenem-resistant isolates.
Methods A total of 205 ESBL-producing Enterobacteriaceae collected from inpatients and outpatients at the All India Institute of Medical Sciences, were identified and tested for antimicrobial susceptibility by the disc diffusion method and Vitek 2 advanced expert system. Ertapenem susceptibility was performed by disc diffusion and Vitek 2 in all the isolates and by E-test in 100 isolates.
Results 191 (93 percent) of the ESBL-producing isolates tested were susceptible to ertapenem. All ertapenem-susceptible isolates were also susceptible to imipenem and meropenem. Isolates with low-level ertapenem resistance retained their susceptibility to imipenem and meropenem, whereas those with high-level ertapenem resistance were resistant to both imipenem and meropenem.
Conclusion Our results suggest that ertapenem may be a viable alternative to other carbapenems for the treatment of infections caused by ESBL-producing clinical isolates. Clinical outcome studies are required to determine if ertapenem is effective for the treatment of infections caused by these organisms.

Keywords: Enterobacteriaceae, ertapenem, extended spectrum ß-lactamase, multidrug-resistant organisms
Singapore Med J 2009; 50(6): 628-632

http://smj.org.sg/sites/default/files/5006/5006a11.pdf
×

Around the Site

Home

About SMJ

For Reviewers

Sign Up for Alerts

Issues

Current Issue

All Issues

Online First

Supplement

CME

For Authors

Instructions for Authors

Submit Manuscript


Follow us on:
        

More Links

Contact Us

Copyright

Advertise

SMJ Forms

Privacy Policy

SMA Home

Copyright 2021. Singapore Medical Association. All Rights Reserved.